The Lancet publishes interim Phase III Ebola vaccine data

Single doses of Ebola vaccine rVSV-EBOV ( VSV-ZEBOV; VSV-EBOV) showed 100% efficacy in an interim analysis of an open-label Guinean Phase III trial. Data from the World Health Organization (WHO)-sponsored trial were published in The Lancet on Friday.

Merck & Co. Inc. (NYSE:MRK) gained exclusive, worldwide rights to rVSV-EBOV from NewLink Genetics Corp. (NASDAQ:NLNK) in 2014. The vaccine was originally developed by the Public Health Agency of Canada. ...